US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

7. New RSV prevention options for infants and pregnant mothers A new RSV prevention option for infants was introduced in 2023: the monoclonal antibody treatment Beyfortus (nirsevimab). This shot is ...